Sugi Predict

Sugi Predict / Compounds / SCHEMBL4043837

SCHEMBL4043837

SCHEMBL4043837

CC(C)(C)NC(=O)c1cccs1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.68
▸ KMT2A Q03164 3/20 0.68
▸ HDAC1 Q13547 1/20 0.62
▸ TSHR P16473 2/20 0.62
▸ ALDH1A1 P00352 4/20 0.57
▸ RAB9A P51151 7/20 0.56
▸ NPC1 O15118 6/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.53
▸ ALOX15 P16050 2/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ CES2 O00748 1/20 0.52
▸ CES1 P23141 1/20 0.52
▸ MAPT P10636 1/20 0.51
▸ ALOX5 P09917 1/20 0.51
▸ PTGS1 P23219 1/20 0.51
▸ PTGS2 P35354 1/20 0.51
▸ LMNA P02545 2/20 0.51
▸ HPGD P15428 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9010792 0.82 TSHR (0.55) MEN1KMT2AHDAC1TSHRALDH1A1
SCHEMBL30433221 0.82 TSHR (0.59) MEN1KMT2AHDAC1TSHRALDH1A1
SCHEMBL8173057 0.81 TSHR (0.63) MEN1KMT2AHDAC1TSHRALDH1A1
SCHEMBL29528205 0.81 CTSC (0.56) MEN1KMT2AHDAC1TSHRALDH1A1
SCHEMBL3229709 0.81 TSHR (0.58) MEN1KMT2AHDAC1TSHRALDH1A1
SCHEMBL3240216 0.81 TSHR (0.58) MEN1KMT2AHDAC1TSHRALDH1A1
SCHEMBL3127881 0.81 HDAC1 (0.62) MEN1KMT2AHDAC1TSHRALDH1A1
SCHEMBL9010814 0.80 TSHR (0.56) MEN1KMT2AHDAC1TSHRALDH1A1
SCHEMBL9010904 0.79 TSHR (0.51) MEN1KMT2AHDAC1TSHRALDH1A1
SCHEMBL28533635 0.79 TSHR (0.51) MEN1KMT2AHDAC1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230053746-A1 IL-17 LIGANDS AND USES THEREOF DICE MOLECULES SV, INC. 2023-02-23 — — US disclosed
US-20220395500-A1 SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF NEURALEXO, INC. 2022-12-15 — — US disclosed
WO-2022235699-A2 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2022-11-10 — — WO disclosed
US-20200247785-A1 IL-17 Ligands And Uses Thereof DICE MOLECULES SV, INC. 2020-08-06 — — US disclosed
EP-3172199-B1 PYRIMIDINE DERIVATIVES AS GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-07-01 — — EP disclosed
CN-109867630-A - 1 receptor modulators of novel glp-1 赛尔基因第二国际有限公司 2019-06-11 — — CN disclosed
CN-105593225-B novel GLP-1 receptor modulators 赛尔基因第二国际有限公司 2019-04-16 — — CN disclosed
US-20170334841-A1 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. 2017-11-23 — — US disclosed
US-20170014419-A1 MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) 2017-01-19 — — US disclosed
US-20170014419-A1 MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) 2017-01-19 — — US disclosed
US-7368452-B2 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2008-05-06 — — US disclosed
WO-2007124181-A2 THIENO-[2,3-D]PYRIMIDINE AND THIENO-PYRIDAZINE COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2007-11-01 — — WO disclosed
US-20070060510-A1 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2007-03-15 — — US disclosed
US-7176208-B2 Prevent reproduction of hepatitis virus ENANTA PHARMACEUTICALS, INC. (US) 2007-02-13 — — US disclosed
US-7176208-B2 Prevent reproduction of hepatitis virus ENANTA PHARMACEUTICALS, INC. (US) 2007-02-13 — — US disclosed
US-6936736-B2 Amide derivative SUMITOMO MANUFACTURING COMPANY LIMITED (JP) 2005-08-30 — — US disclosed
EP-1034783-B1 AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS SUMITOMO PHARMA (JP) 2004-12-15 — — EP disclosed
US-20020147204-A1 Amide derivative SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2002-10-10 — — US disclosed
US-6384033-B1 DRUGS FOR VISION DEFECTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-05-07 — — US disclosed
EP-1034783-A1 AMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2000-09-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230053746-A1 IL-17 LIGANDS AND USES THEREOF IL17A, IL2, IL15 MEN1 2700/4885KMT2A 4343/4885HDAC1 1200/4885
US-20220395500-A1 SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF IRF3, IRF2BP2, STAT1 MEN1 4664/4885KMT2A 3862/4885HDAC1 1084/4885
US-20200247785-A1 IL-17 Ligands And Uses Thereof IL17A, IL2, IL15 MEN1 2700/4885KMT2A 4343/4885HDAC1 1200/4885
US-20170334841-A1 TETRACYCLINE COMPOUNDS TUBB, TUBA1A, TUBA1C MEN1 2645/4885KMT2A 2825/4885HDAC1 49/4885
US-20070060510-A1 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors PRSS1, SPINT2, HPN MEN1 3743/4885KMT2A 2442/4885HDAC1 631/4885
US-20020147204-A1 Amide derivative ALDH1A2, NR1H2, HDAC3 MEN1 3899/4885KMT2A 1003/4885HDAC1 5/4885
US-20170014419-A1 MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS AGTR2, MME, AGTR1 MEN1 725/4885KMT2A 2336/4885HDAC1 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.